Articles tagged "Liver transplantation"

2016 American Transplant Congress
Large Single-Center Experience of Sofosbuvir and Ledipasvir Therapy for the Treatment of Post-Liver Transplant Patients with Hepatitis C Virus.
J. Wedd, R. Ford, J. Norvell, S. Parekh, N. Cheng, N. Young, A. Patel, R. Maheshwari, R. Vora, O. Mgbemena, J. Spivey, A. Pillai.
Medicine, Emory University, Atlanta, GA.
Background/Aims: Controlled trials of direct acting antiviral therapy for Hepatitis C Virus (HCV) show impressive sustained virologic response (SVR) rates, but post-transplant data of sofosbuvir…
2016 American Transplant Congress
Portal Vein Complication After Living Donor Right Hepatectomy.
D.-H. Jung, S.-G. Lee, S. Hwang, K.-H. Kim, C.-S. Ahn, D.-B. Moon, T.-Y. Ha, G.-W. Song, W.-J. Kim, S.-H. Kim, W.-H. Kang, J.-H. Kwon, E.-K. Jwa, H.-D. Cho.
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
BackgroundLiving donor hepatectomy may carry a significant risk of morbidity and mortality for the otherwise healthy donor. Portal vein (PV) complication after donor hepatectomy is…
2016 American Transplant Congress
Effect of Modifying Life Support Withdrawal Practices on Outcomes of Donation After Circulatory Death in Liver Transplantation: A Meta-Analysis.
Y. Cao,^1,2 S. Shahrestani,³ H. Chew,^2,4 M. Crawford,⁵ P. Macdonald,^1,2,4 J. Laurence,^3,5,7 W. Hawthorne,^3,6 K. Dhital,^1,2,4 H. Pleass.^3,5,6
¹Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia; ²Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; ³Sydney Medical School, University of Sydney, Sydney, NSW, Australia; ⁴Cardiac Transplant Unit, St. Vincent's Hospital, Sydney, NSW, Australia; ⁵Australian National Liver Transplant Unit, Royal Prince Alfred Hospital, Sydney, NSW, Australia; ⁶The Department of Surgery, Westmead Hospital, Sydney, NSW, Australia; ⁷Institute of Academic Surgery, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
Aim. Donor warm ischaemic time is identified as the main risk factor for poor outcomes in liver transplantation using donation after circulatory death (DCD) compared…
2016 American Transplant Congress
The Impact of Gender Discordance on Graft Survival Among Liver Transplant Recipients.
J. Moore, X. Luo, A. Massie, T. Purnell, D. Mogul, D. Segev.
Johns Hopkins School of Medicine, Baltimore.
Past studies have shown inferior liver graft survival in gender-discordant recipient/donor pairings compared to gender-matched pairings, particularly in male recipients of female donor livers. However,…
2016 American Transplant Congress
LACE Index Risk Assessment Tool Predicts Liver Transplant Readmissions.
A. Masoumi,¹ R. Barth,² J. LaMattina,² D. Bruno,² L. Hebert,¹ N. Schluterman,³ S. Hanish.²
¹University of Maryland Medical Center, Baltimore, MD; ²Department of Surgery, University of Maryland School of Medicine, Baltimore, MD; ³Department of Epidemiology, University of Maryland School of Public Health, Baltimore, MD.
Background:One-fifth of Medicare patients are readmitted to the hospital an annual cost of $17.4 billion. The LACE Index (Length of stay, Acuity of the admission,…
2016 American Transplant Congress
Outcomes of Arterial and Venous Conduits for Vessel Reconstruction in Liver Transplantation.
J. Tan,¹ G. Oniscu.²
¹University of Edinburgh, Edinburgh, United Kingdom; ²Liver Transplant Unit, Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
Background: The use of hepatic artery (HA) and portal vein (PV) conduits is a recognised alternative technique in vessel reconstruction during liver transplantation. The hepatic…
2016 American Transplant Congress
Shifts of Etiology in Patients with in Bacteremic Liver Transplant Recipients.
S. Kim,¹ Y. Kim,¹ J. Choi,¹ S. Yoon,¹ G. Na,² J. Kim,² I. Moon,² Y. Yoo,² D. Kim.²
¹Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; ²Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
BackgroundBacteremias are the most frequently occurring infectious complications after liver transplantation. The spectrum of pathogens and patters of antibiotics susceptibility can vary owing to the…
2016 American Transplant Congress
The Heterogenous Genomic Landscape of Unresectable Hepatoblastoma Requiring Liver Transplantation: Prognostic Implications.
M. Ningappa, B. Higgs, S. Ranganathan, C. Ashokkumar, R. Sindhi.
Surgery, Children's Hospital of Pittsburgh of UPMC and University of Pittsburgh, Pittsburgh, PA.
Background: Hepatoblastoma, the most common pediatric liver malignancy, is cured by chemotherapy and surgical resection. Locally invasive/multifocal tumors require liver transplantation (LTx). A unique tumor…
2016 American Transplant Congress
Outcomes of Ribavirin Free Treatment of Recurrent Genotype 1 , Hepatitis C Infection Post Liver Transplant.
D. Jones,¹ S. Baggett,¹ M. Shoreibah,² O. Massoud.²
¹Department of Pharmacy, UAB Hospital, Birmingham, AL; ²Department of Gastroenterology, UAB Hospital, Birmingham, AL.
Background. With the development of direct-acting antivirals, the treatment of Hepatitis C Virus (HCV) has become a rapidly changing area of medical practice. Data on…
2016 American Transplant Congress
Live Donor Liver Transplantation for NASH: The Toronto Experience.
A. Barbas, N. Goldaracena, M. Dib, M. Marquez, G. Sapisochin, D. Al-Adra, I. McGilvray, M. Cattral, P. Greig, D. Grant.
General Surgery, Multi-Organ Transplant, University of Toronto, Toronto, ON, Canada.
Background:Non-alcoholic steatohepatitis (NASH) is an increasingly common indication for liver transplantation in North America. In the context of organ scarcity and significant waitlist mortality, our…